In the JournalsFrom OT Europe

Adalimumab seen as safe for treatment of Dupuytren’s disease

A single intramodular injection of 40 mg adalimumab in patients with Dupuytren’s disease was safe and showed down regulation of the myofibroblast phenotype as demonstrated by decreased levels of alpha-smooth muscle actin and type I procollagen proteins, according to results from a phase 2a randomized trial.

Researchers identified 28 patients with Dupuytren’s disease and randomized patients to receive an injection of adalimumab or the equivalent volume of placebo. Of the 28 patients, eight patients were placed in 15-mg of adalimumab cohort, 12 patients were in the 35-mg adalimumab cohort and eight patients were in the 40-mg adalimumab cohort. The levels of mRNA expressions for alpha-smooth muscle actin (ACTA2) were the main outcome measures assessed. Other outcomes included levels of alpha-smooth muscle actin (α-SMA) and collagen proteins.

Results showed patients treated with 40 mg adalimumab compared with placebo-treated patients had significantly lower levels of α-SMA. Investigators noted no change in mRNA levels for ACTA2, COL1A1, COL3A1 and CDH11. Patients treated with 40 mg adalimumab vs. those treated with placebo had significantly lower levels of procollagen type I protein expression. Two serious events were seen; however, these were unrelated to the drug. – by Monica Jaramillo

 

Disclosures: Nanchahal reports he receives grants from Wellcome Trust, the Department of Health and 180 Therapeutics LP; and has patent PCT/EP2011/069147 issued to 180 Therapeutics. Please see the full study for a list of all other authors’ relevant financial disclosures.

A single intramodular injection of 40 mg adalimumab in patients with Dupuytren’s disease was safe and showed down regulation of the myofibroblast phenotype as demonstrated by decreased levels of alpha-smooth muscle actin and type I procollagen proteins, according to results from a phase 2a randomized trial.

Researchers identified 28 patients with Dupuytren’s disease and randomized patients to receive an injection of adalimumab or the equivalent volume of placebo. Of the 28 patients, eight patients were placed in 15-mg of adalimumab cohort, 12 patients were in the 35-mg adalimumab cohort and eight patients were in the 40-mg adalimumab cohort. The levels of mRNA expressions for alpha-smooth muscle actin (ACTA2) were the main outcome measures assessed. Other outcomes included levels of alpha-smooth muscle actin (α-SMA) and collagen proteins.

Results showed patients treated with 40 mg adalimumab compared with placebo-treated patients had significantly lower levels of α-SMA. Investigators noted no change in mRNA levels for ACTA2, COL1A1, COL3A1 and CDH11. Patients treated with 40 mg adalimumab vs. those treated with placebo had significantly lower levels of procollagen type I protein expression. Two serious events were seen; however, these were unrelated to the drug. – by Monica Jaramillo

 

Disclosures: Nanchahal reports he receives grants from Wellcome Trust, the Department of Health and 180 Therapeutics LP; and has patent PCT/EP2011/069147 issued to 180 Therapeutics. Please see the full study for a list of all other authors’ relevant financial disclosures.